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Growth hormone (GH) release-inhibiting activity was originally detected 
accidentally during investigations into the distribution of GH releasing 
factor in the rat hypothalamus (Krulich et al, 1968). Thereafter it was shown 
that this GH release-inhibiting peptide, called somatostatin, is a cyclic 
peptide consisting of 14 amino acids (Brazeau et al, 1973). The phylogeny, 
the anatomic distribution, the mechanisms of action, and the functional 
significance of somatostatin have been reviewed in detail by Reichlin 
(1983a,b). 
The name somatostatin s, in fact, inappropriate because the peptide is 
distributed widely throughout the body in cells which have nothing to do 
with the regulation of GH secretion. In the hypothalamus somatostatin is a 
neurohormone which reaches the pituitary gland via the portal circulation, 
where it inhibits the secretion of normal GH and thyrotrophin (thyroid 
stimulating hormone, TSH). Somatostatin is also present in high amounts 
throughout the central and peripheral nervous ystem, where it influences a 
variety of functions as a neurotransmitter or neurohormone. The peptide is 
also found in discrete secretory cells of classical epithelial appearance in all 
parts of the stomach and the gut where it inhibits, via autocrine and 
paracrine actions, the secretion of gastrin, pepsin and hydrochloric acid in 
the stomach, bile secretion, and the release of secretin and vasoactive 
intestinal polypeptide. The secretion of somatostatin i to the lumen of the 
digestive tract ('lumone'), influences the contractility ofthe gastro-intestinal 
tract and the absorption of fluids. Finally, somatostatin i hibits both 
exocrine and endocrine pancreatic function; apart from an inhibitory effect 
on pancreatic fluid, bicarbonate and enzyme production, somatostatin 
(produced in the D-cells of the pancreatic islets) influences carbohydrate 
metabolism via paracrine inhibitory actions on the release of insulin and 
glucagon (see Guillemin, 1978; Reichlin, 1983a,b). 
Somatostatin, therefore, is present and plays an inhibitory role in the 
normal regulation of at least three organ systems of humans and other 
species: (i) the central nervous ystem, the hypothalamus and the pituitary 
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gland; (ii) the gastro-intestinal tract; (iii) the exocrine and endocrine 
pancreas. It was thus expected to be of therapeutic value in clinical con- 
ditions involving hyperfunction of these systems. However, the multiple 
simultaneous effects of somatostatin  these organ systems, the need for 
intravenous administration f the peptide, its short duration of action (half- 
life in the circulation of about 3 min), and the post-infusion rebound hyper- 
secretion of hormones greatly diminished the initial enthusiasm for its 
clinical use (Guillemin, 1978). 
Many attempts have been made in recent years to synthesize analogues of 
somatostatin that do not have the disadvantages of the native peptide. 
Preliminary clinical and preclinical results with several different analogues 
have been reported (Vale et al, 1978; Cai et al, 1986; Gottesman et al, 1986). 
Using step-by-step modification of the conformationally-stabilized, c ntral, 
essential part of the somatostatin molecule, Bauer et al (1982) succeeded in 
synthesizing an analogue which did not have most of the disadvantages of 
the native peptide. In monkeys this analogue, code named SMS 201-995 
(Sandostatin, octreotide, see Figure 1) inhibits the secretion of GH, 
glucagon and insulin 45, 11, and 1.3 times more actively, respectively, than 
native somatostatin. It is currently unknown why Sandostatin hibits GH 
secretion more powerfully than insulin secretion. The analogue is highly 
resistant to enzymatic degradation which explains its much longer and more 
powerful inhibitory effect on GH secretion. 
Pharmacokinetic studies howed that a single subcutaneous injection of 
50 txg of Sandostatin normal subjects resulted, after 30-60 min, in peak 
plasma drug concentrations of 1.9-2.7 ng/ml, and that it has an elimination 
half-life of 113 min (del Pozo et al, 1986). Although not yet of therapeutic 
interest, it was shown thereafter that the oral administration f 2 mg of this 
analogue together with 75 g of glucose also resulted in 'therapeutic' levels in 
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Figure 1. The amino acid sequences of natural somatostatin a d the synthesized analogue 
Sandostatin. 
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the circulation (Williams et al, 1986). A rather unexpected observation with 
regard to the inhibitory effect of Sandostatin on hormone secretion is the 
absence of rebound hypersecretion (Lamberts et al, 1985a). Figure 2 shows 
the course of the plasma GH concentrations of one of our acromegalic 
patients on subsequent days when a placebo or 50 ~xg Sandostatin was 
administered subcutaneously at 8.15 am. The analogue suppressed circulat- 
ing GH levels almost completely for 8-10 h, after which they returned slowly 
to control values. 
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Figure 2. The effect of the subcutaneous administration of 50 l~g Sandostatin (SMS 201-995) at 
8.15 h on plasma GH levels (O- -  O) in an untreated acromegalic patient in comparison with the 
effect of a placebo at 8.15 h on another day (©- -O) .  
ACROMEGALY 
The potential use of somatostatin analogues like Sandostatin i  the long- 
term control of tumoral hypersecretion f hormones has been demonstrated 
most clearly in patients with GH-secreting pituitary tumours. A single 
subcutaneous injection of 50 Ixg of Sandostatin suppressed mean GH levels 
after 2-6 h to less than 5 Ixg/1 in 24 of 41, and by more than 50% in 34 of 41 
acromegalic patients (Lamberts et al, 1986b). High numbers of high-affinity 
somatostatin receptors have been detected on most GH-secreting pituitary 
tumours removed from acromegalic patients (Reubi and LandoR, 1984). 
Recently Reubi and Landolt (1989) showed that in acromegalics the 
response of GH to Sandostatin i vivo was closely related to the number of 
somatostatin receptors which were present on the tumour tissue obtained at 
subsequent trans-sphenoidal operation. 
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Several reports have been published which show that most acromegalic 
patients respond very well clinically to chronic therapy with Sandostatin 
(Plewe et al, 1984; Ch'ng et al, 1985; Lamberts et al, 1985b; Oppizzi et al, 
1986; Lamberts et al, 1987b). Therapy with 200-300 ~g Sandostatin daily in 
two or three injections caused amarked clinical improvement within days or 
weeks in virtually all patients, with a diminution or disappearance of
complaints like excessive perspiration, headaches, paraesthesias and 
fatigue. After weeks or months of therapy regression of soft tissue swelling 
and even of facial coarsening was noted. The mean 24 h GH levels decreased 
during therapy by more than 80%. 
The extent of GH suppression during chronic Sandostatin therapy can be 
predicted from the initial acute response of GH to a single dose of 50 p~g of the 
drug (Lamberts et al, 1988c). During chronic therapy with Sandostatin, a 
tendency remained for the GH levels to increase towards the next injection 
(Lamberts et al, 1985b). However, this tendency diminished over time in 
most patients (Lamberts et al, 1987b). Of great interest isthe observation that 
the initially raised serum concentrations of somatomedin-C (Sm-C, insulin- 
like growth factor I, IGF-I) declined uring Sandostatin therapy in parallel 
with the decrease in the mean 24 h GH levels. In Figure 3 the course of the 
mean 24 h GH and the Sm-C levels of eight acromegalic patients is shown 
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Figure 3. The course of serum Somatomedin-C (Sm-C/IGF-I) and the mean 24-h GH concen- 
trations in eight acromegalic patients during therapy for 2 years with 200-300 ixg Sandostatin 
daily. (The upper limit of normal of Sm-C = 2.2 U/ml.) 
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during long-term treatment with Sandostatin (300 jxg daily) for 24 months. A 
complete normalization of Sm-C levels was eventually achieved in more than 
50% of the acromegalic patients. So, it seems possible to manipulate the 
circulating levels of one of the proven tumour growth factors (IGF-I) by 
chronic administration of an analogue of an endogenous inhibitory tissue 
'growth' factor. 
A decrease in pituitary tumour size during Sandostatin treatment was 
observed on computerized tomography scanning in more than half the 
acromegalic patients (Lamberts et al, 1985b, 1987b; Barkan et al, 1988). 
Tumour size reduction, however, was less impressive than that observed 
during bromocriptine treatment of most prolactin (PRL)-secreting pituitary 
tumours. Tumour shrinkage has been suggested to occur via a decrease in 
the size of individual tumour cells caused by their decreased hormonal 
content, rather than via a cytotoxic effect of Sandostatin (Lamberts et al, 
1987b, 1988c; for review see Lamberts, 1988). The marginal shrinkage of the 
pituitary tumours during Sandostatin therapy might be partially explained 
by two recent observations: (i) Reubi et al (1987b) visualized somatostatin 
receptor sites on a number of GH-secreting tumours and showed that their 
distribution is often heterogeneous, suggesting that considerable numbers 
of tumour cells are not sensitive to somatostatin; (ii) Hofland et al (1989) 
recently showed by studying hormone release of individual human pituitary 
tumour cells with the reverse haemolytic plaque assay, that in most tumours 
only a minority of tumour cells release the majority of the total amount of 
GH produced. Especially these 'active' tumour cells seem sensitive to 
Sandostatin, while the majority of the less active tumour cells hardly 
respond. 
Acromegaly often causes distressing disfigurement and a variety of 
complaints. When treated ineffectively it approximately doubles mortality 
at all ages as a result of cardiovascular disease associated with hypertension, 
diabetes mellitus and cancer. Effective and safe long-term medical 
treatment with Sandostatin is of great benefit in as many as 30-35% of 
acromegalics, in whom trans-sphenoidal surgery was unsuccessful orcontra- 
indicated, or in those patients in whom the effects of radiotherapy have to be 
awaited (for review see Lamberts, 1988). There seems little doubt that 
Sandostatin is in general superior to dopamine agonist herapy with bromo- 
criptine (Lamberts et al, 1986c), but the side-effects of long-term Sando- 
statin treatment will need evaluation (see below). 
OTHER PITUITARY TUMOURS 
Somatostatin s, under normal conditions, a physiological inhibitory regu- 
lator of GH secretion. However, somatostatin also reaches the other 
anterior pituitary cells. An inhibitory response to somatostatin of hormone 
secretion by normal corticotrophs, lactotrophs and thyrotrophs, however, 
depends mainly on the microenvironment of these cells, especially with 
regard to their own feedback hormones. In the absence of glucocorticoids 
the corticotrophs are sensitive to the inhibitory effect of somatostatin 
34 s .w. J .  LAMBERTS ET AL 
(Lamberts et al, 1989b); in the presence of increasing oestradiol concentra- 
tions, dopamine sensitivity of the lactotroph decreases while the sensitivity 
to somatostatin i creases to the same extent, and in the absence of thyroid 
hormone the thyrotroph is more sensitive to somatostatin (Lamberts et al, 
1989b). These changes are probably not mediated via postreceptor effects 
but seem to be regulated via a change in the number and/or affinity of 
somatostatin receptors on these respective cells (Viguerie et al, 1987). 
Interestingly somatostatin receptors remain present on many human 
pituitary tumours which originate from adrenocorticotrophic ormone 
(ACTH), TSH and PRL cells, but also on part of non-functioning pituitary 
tumours (Reubi et al, 1987b). This makes these patients good candidates for 
treatment with long-acting somatostatin analogues. Indeed inhibition of 
hormone release and tumour shrinkage have been reported uring therapy 
with Sandostatin i  patients with TSH- and infiltrating ACTH (Nelson's 
Syndrome) secreting pituitary tumours (Comi et al, 1986; Guillausseau etal, 
1987; Lamberts et al, 1989a). 
SIDE-EFFECTS OF SANDOSTATIN THERAPY 
Sandostatin was reported to be well tolerated inmost patients (Lamberts et al, 
1985b, 1987b; Kvols et al, 1986, 1987). Gastro-intestinal reactions are 
common during the first days of therapy; these consist of crampy abdominal 
pains, flatulence, loose stools, diarrhoea nd steatorrhoea. The increase in 
the fat content of the faeces during Sandostatin therapy is only minimal in 
most patients and normalizes spontaneously after a few weeks. No nutritional 
deficiencies related to malabsorption have been reported. In a few patients 
gallstone formation was observed, which might be a side-effect of long-term 
treatment with Sandostatin. 
Because of its inhibitory action on insulin release Sandostatin may impair 
postprandial glucose tolerance. However, during chronic therapy with 
Sandostatin doses as high as 450 ~g/day, no clinically significant deterio- 
ration of glucose tolerance was observed in 50 patients with acromegaly, 
endocrine pancreatic tumours and carcinoids (Lamberts et al, 1985b, 1987b; 
Kvols et al, 1986, 1987). It is not yet known whether the induction of a mild 
diabetic state during Sandostatin treatment, will give rise to the develop- 
ment of secondary complications a  seen in diabetic patients. Interestingly, 
no desensitization, tachyphylaxis, or down-regulation of the effect of 
Sandostatin on 'normal' insulin secretion was noted in acromegalic patients 
treated for up to 2 years (Lamberts et al, 1987b). 
ENDOCRINE PANCREATIC TUMOURS 
Functional endocrine tumours originating from the neuroendocrine peptide- 
secreting cells of the endocrine pancreas and of the gastro-intestinal tract are 
relatively rare. The majority of these tumours originate from the pancreas but 
they may also occur in the stomach, the duodenum or intestines (Bloom and 
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Polak, 1980). These tumours ecrete polypeptide hormones and traditionally 
their name is derived from the specific clinical syndromes caused by the 
hypersecretion f the hormones (e.g. gastrinomas, glucagonomas, vipomas, 
insulinomas). Often these tumours tart o secrete other hormones during the 
follow-up, which then leads to the appearance of new clinical syndromes 
(Wynick et al, 1988). 
With the exception of insulinomas most tumours are malignant and in 
many patients metastases are present at the time of initial clinical presen- 
tation (Stefanini et al, 1974). The optimal treatment ofmalignant endocrine 
pancreatic turnouts has not yet been established. Surgery is the primary 
treatment, but debulking of the turnout is often the only option when 
metastases in lymph nodes and especially in the liver are present at 
operation. Palliative treatment with cytostatic drugs (Moertel et al, 1980) 
has been shown to result in transient improvement in about 35% of patients. 
However, none of these treatments cures the disease and the often distress- 
ing clinical symptomatology of most patients i especially difficult o control. 
However in some instances ymptomatic treatment can be achieved. For 
example non-competitive Hz-blocking drugs successfully block the hyper- 
secretion of gastric acid in most gastrinoma patients (Lamers et al, 1984). 
Sandostatin has been shown to be especially beneficial in the treatment of
the clinical syndromes caused by hypersecretion f hormones: severe diar- 
rhoea, dehydration and hypokalaemia, peptic ulceration, life-threatening 
attacks of hypoglycaemia and necrolytic skin lesions can be well controlled 
during chronic therapy with 100-450 txg Sandostatin daily in most patients 
with pancreatic tumours secreting VIP, gastrin, insulin and glucagon 
(Bonfils, 1985; Maton et al, 1985; Wood et al, 1985; Anderson and Bloom, 
1986; O'Dorisio, 1986; Vinik et al, 1986; Kvols et al, 1987; Eriksson et al, 
1988; Woltering et al, 1988). Even the often very aggressive form of 
Cushing's yndrome caused by ectopic secretion of ACTH from a metastatic 
gastrinoma was well controlled in several patients during Sandostatin 
treatment (Lamberts et al, 1988b; Ruszniewski et al, 1988). 
Summarizing the experience of Sandostatin therapy in patients with 
metastatic endocrine pancreatic tumours everal conclusions can be drawn: 
1. The initial clinical response to Sandostatin therapy seems mainly 
dependent on the presence of somatostatin a alogue receptors on these 
tumours. Analysing a group of 18 metastatic endocrine pancreatic 
tumours we found high affinity binding sites for the tyr3-derivative of
Sandostatin on 14 of them (see Table 1 and Reubi et al, 1987a). 
Table 1. The presence of somatostatin receptors on endocrine 
pancreatic turnouts of 18 patients. 
Somatostatin a alogue (204-090) receptors 
Type of tumour Positive Negative 
Gastrinoma 6 0 
Insulinorna 4 3 
Vipoma 4 1 
TOTAL 14 4 
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Interestingly in insulinomas little or no binding with Sandostatin was 
observed in several cases, while simultaneously binding studies with 
somatostatin-28 showed high numbers of receptors for this endogenous 
peptide (Reubi et al, 1987a). In one of these insulinoma patients the 
acute administration of 50 ~g Sandostatin resulted in an acute hypo- 
glycaemic attack: tumorous hypersecretion f insulin was not affected, 
but the release of the counter-regulatory hormones glucagon and GH, 
was suppressed by Sandostatin, and probably associated with delay in 
time of transit hrough the gut and of glucose absorption. Therefore it 
seems advisable to select insulinoma patients for Sandostatin therapy 
only after a well-controlled trial in which the first dose of the drug is 
administered in hospital where glucose can be administered intra- 
venously if necessary. In this regard it is interesting to note that neonatal 
hypoglycaemia in newborns with nesidioblastosis can be controlled with 
Sandostatin (Bruining et al, 1986). 
2. The duration of the beneficial effects of Sandostatin on clinical sympto- 
matology of patients with metastatic endocrine pancreatic tumours is 
highly variable. Mild worsening of symptoms and increasing tumour- 
related hormone concentrations were observed during long-term 
therapy with Sandostatin, but increasing the dose of the analogue 
initially reversed these problems in most patients (Anderson and 
Bloom, 1986; Williams et al, 1987). Some beneficial effects of Sando- 
statin in this type of patient, like a decrease in contractility of the 
gastro-intestinal tract, may be direct and not mediated via the inhibition 
of tumoral hormone secretion. Often these beneficial effects will remain 
even if the sensitivity of the tumours to Sandostatin declines. Eventually 
tumour cells without somatostatin receptors will develop, and the 
therapeutic effect of Sandostatin decreases in parallel with signs and 
symptoms of turnout progression. Unfortunately, however, in excep- 
tional cases a sudden escape from Sandostatin can also occur early after 
the initiation of therapy. This resistance to Sandostatin might well be 
caused by down-regulation of the somatostatin receptors on these 
tumours. Indeed somatostatin receptor down-regulation is demon- 
strable under certain experimental conditions, although it is not yet 
proven to occur in resistant tumours (Viguerie et al, 1987). The sudden 
occurrence of insensitivity to Sandostatin is clinically of potential 
danger especially in vipoma and insulinoma patients where hypo- 
kalaemic acidosis, dehydration and hypoglycaemic attacks can suddenly 
reappear (Koelz et al, 1987; Lamberts et al, 1988a). 
3. There is very little evidence so far that Sandostatin controls tumour 
growth in this type of patient. Most patients treated chronically with 
Sandostatin had metastatic disease initially, especially affecting the 
liver. Gorden (1989) summarized the literature and reported that out of 
a total of 46 patients (five insulinoma, 16 gastrinoma, ten vipoma, eight 
glucagonoma nd seven other islet cell turnouts), who were treated 
chronically with Sandostatin i a dose varying between 200 and 1500 g/ 
day, tumour size increased in 20, remained unchanged in 18 and actually 
decreased in eight patients. 
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. The place of Sandostatin i the treatment of patients with metastatic 
endocrine pancreatic tumours reflects its high efficacy in controlling the 
clinical signs and symptoms caused by hypersecretion f hormones. A
high success rate with regard to a decrease in stool volume, improve- 
ment of systemic electrolyte and fluid imbalance, healing of skin lesions 
and peptic ulceration and a decrease in the number of attacks of hypo- 
glycaemia can be expected. In this respect Sandostatin is able to 
improve the quality of life in most of these patients, while also the 
duration of the stay in hospital and the number and the severity of the 
life-threatening complications related to hormonal hypersecretion 
diminish. However, Sandostatin s a palliative therapy and it will hardly 
affect or change the classic therapeutic approach in this type of patient, 
which consists of surgery (debulking) and selective arterial emboliza- 
tion of the tumour and its metastases. In our opinion Sandostatin 
therapy can be tried, however, as a second line of therapy, while 
cytotoxic therapy with drugs like streptozotocin must be considered 
thereafter when the sensitivity of the turnout to Sandostatin declines. 
CARCINOIDS 
Carcinoids are often malignant umours which originate from entero- 
chromaffin cells throughout the body, but especially from the gastro- 
intestinal tract and the lung (Pearse t al, 1974). Patients with the metastatic 
carcinoid syndrome xperience attacks of flushing, diarrhoea nd some- 
times wheezing and right heart failure because of tricuspid valve insuffi- 
ciency. The symptoms are related to hypersecretion of serotonin and 
tachykinins by carcinoids. However, especially in carcinoids derived from 
the foregut and midgut, clinical symptomatology occurs when metastases 
have developed which secrete their products directly in the systemic ircu- 
lation (e.g. liver metastases). Because most carcinoids are relatively slow- 
growing tumours, the symptoms caused by the biochemical products 
secreted by the tumour dominate the clinical picture. These patients 
frequently become invalided by the severe diarrhoea, flushing attacks and 
congestive heart failure. Many carcinoid patients die from the complications 
of long-standing hormonal hypersecretion, rather than from tumour pro- 
gression (Kvols et al, 1986; Hodgson and Maton, 1987). 
Kvols et al (1986) carried out careful studies on the effects of Sandostatin 
treatment of patients with the malignant carcinoid syndrome. Chronic 
therapy with 450 ~g Sandostatin daily caused an impressive symptomatic 
and biochemical response in virtually all 25 patients tudied. Flushing and 
diarrhoea ssociated with the syndrome were promptly relieved in 22 
patients. Eighteen of the 25 patients had a decrease of 50% or more in their 
urinary 5-hydroxyindolacetic acid excretion, as compared with the pretreat- 
ment values. The median duration of this biochemical response was more 
than 12 months. Thirteen of these patients had tumours that could be 
assessed objectively by linear or bidimensional measurements. In eight of 
these patients, the tumour remained unchanged, whereas (incomplete) 
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tumour egression was observed in the other five patients during Sandostatin 
therapy. A recent study of 35 carcinoids howed that 80% of the tumours 
contained a high density of somatostatin receptors (Reubi et al, unpublished 
data). 
The current optimal therapy of malignant carcinoid isease seems com- 
parable to that advocated for metastatic endocrine pancreatic tumours (see 
above). Surgical debulking only alleviates ymptomatology, but many 
patients are in a bad clinical condition. Sandostatin has been shown to control 
effectively acute hypertension i  carcinoid crises, as they can occur during 
anaesthesia (Kvols, 1986). Arterial embolization of the tumour and its 
metastases has been shown to be temporarily effective in some patients 
(Maton et al, 1983). Chemotherapy with combinations of agents, often 
including streptozotocin, s in most patients disappointing (Kvots, 1986). In a 
recent review Hodgson (1988) concluded that symptomatic control of 
hormonal hypersecretion with simple blocking agents like serotonin-blockers 
(ketanserin) and, if this is not effective, Sandostatin s the primary treatment 
of the metastatic carcinoid syndrome. The quality of life improves dramatic- 
ally during Sandostatin therapy while the occurrence of secondary compli- 
cations like cachexia, dehydration, tachyarrhythmias, congestive heart 
failure and bronchoconstriction aredelayed. We suspect that hese beneficial 
effects of Sandostatin will be shown to contribute significantly to longer 
survival of these patients. Whether or not the drug also controls tumour 
growth remains unanswered at present. Eventually, when the tumour 
becomes insensitive to Sandostatin, embolization, surgical debulking and 
chemotherapy should be considered. 
EFFECTS IN EXPERIMENTAL TUMOURS 
Somatostatin analogues have been shown to inhibit the growth of a variety 
of transplantable tumours in different animals (see Lamberts et al, 1987a; 
Schally, 1988). The subcutaneous administration of natural somatostatin 
and three different analogues indoses of 30 jxg, once or twice daily for 14-30 
days to rats bearing the Swarm chondrosarcoma reduced tumour volume 
and/or weight significantly (Redding and Schally, 1983). Chronic admin- 
istration of Sandostatin (1.25mg/kg/day, 5 days per week for 5 weeks) 
inhibited tumour volume of these chondrosarcomas by 48% (Reubi, 1985). 
Somatostatin analogues inhibit tumour growth and prolong the survival of 
mice bearing the Dunn osteosarcoma (Cai et al, 1986), and inhibited the 
growth of acinar pancreatic carcinomas in rats (Redding and Schally, 1984; 
Klijn et al, 1988), a ductal pancreatic adenocarcinoma growing in hamsters 
(Cai et al, 1986), the transplantable prolactin-secreting rat pituitary 
carcinoma 7315a (de Quijada et al, 1983; Lamberts et al, 1986a), trans- 
plantable insulinomas in hamsters (Reubi, 1985), the MT/W9A mammary 
adenocarcinoma in the rat (Cai et al, 1986) and the Dunning R3327H 
prostate carcinoma inthe rat (Cai et al, 1986; Siegel et al, 1988). In addition 
somatostatin a alogue administration has been shown to inhibit effectively 
the growth of transplanted human adenocarcinomas of the pancreas (Upp et 
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al, 1988) and the colon (Palmer Smith and Solomon, 1988) and human small 
cell lung cancers (Taylor et al, 1988a) which were transplanted in nude mice. 
Somatostatin analogues seem to exert heir inhibitory action  tumour 
growth in the experimental tumours mentioned above via one or more of the 
following mechanisms (Table 2; Reubi, 1985; Lamberts et al, 1986a): 
1. Inhibition of the secretion of hormones which are involved in the 
regulation of tumour growth, like GH, insulin and/or other hormones of 
the gastro-intestinal tract; 
2. Direct or indirect (via GH) inhibition of the formation of IGF-I and/or 
other growth factors which exert a stimulatory effect on the growth of 
tumours; 
3. Inhibition of angiogenesis. O'Dorisio (1986) showed in several in vitro 
models that Sandostatin exerts a powerful inhibitory effect on 
angiogenesis e pecially if this is evoked (Fassler et al, 1988); 
4. A direct inhibitory effect on the turnout. 
Table 2. Mechanism of action of the tumour growth inhibitory effects of somatostatin 
analogues. 
1. Inhibition of the secretion of GH, insulin and/or other gastrointestinal hormones? 
2. Inhibition of IGF-I production and/or of other tumour growth factors? 
3. Inhibitor of angiogenesis? 
4. Direct antimitotic effect on the tumour cells? 
Actions 1 and 4 may be receptor-mediated. 
Mechanisms 1and 4 may be mediated via specific somatostatin receptors. 
This last mechanism of action of a direct antiproliferative ffect of 
somatostatin (analogues) eems to be of considerable importance. Somato- 
statin inhibits DNA synthesis and cell replication induced by epidermal 
growth factor (EGF) both in gerbil fibroma and Hela cells (Mascardo and 
Sherline, 1982). Both native somatostatin and two of its analogues directly 
inhibit the proliferation of the human breast cancer cell line MCF-7 
(Setyono-Han et al, 1987), while direct antiproliferative effects of Sando- 
statin on primary breast cancer cell lines were also reported (Scambia et al, 
1988). In a human pancreatic ancer cell line (MIA PaCa-2) somatostatin 
was shown to reverse EGF-stimulated cell growth (Liebow et al, 1986), 
while somatostatin also selectively suppressed insulin-induced proliferation 
of cultured human hepatoma cells (Chou et al, 1987). In Figure 4 Sando- 
statin is shown to reverse both basal and the IGF-I (somatomedin-C)- 
induced stimulation of PRL release and thymidine incorporation in the 
cultured tumour cells prepared from a transplantable pituitary carcinoma 
(Lamberts et al, 1986a). In several of these models, the tumours were shown 
to contain somatostatin receptors. These data and those presented at the 
beginning of the chapter suggest that somatostatin may be one of a class of 
hormones that act as endogenous tumour growth inhibitors or as modulators 
of growth stimulatory peptides. 
Several observations from studies with transplantable tumours have 
shown that he dose and schedule of administration of somatostatin 
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Figure 4. The effect of Sandostatin (SMS 201-995) on PRL release and 3H-thymidine 
incorporation by cultured cells prepared from the transplantable PRL-secreting rat pituitary 
tumour 7315b (mean + SEM; 4 dishes per group). 
analogues may be important factors in the development ofdesensitization r 
tachyphylaxis oftheir inhibitory effects on plasma GH, insulin and/or IGF-I 
concentrations. This is especially important in the rat (Lamberts et al, 
1987c), but might also pertain to studies in man (Klijn et al, unpublished 
data). In addition, the occurrence of 'down-regulation' of somatostatin 
receptors on tumours during chronic therapy with somatostatin analogues 
might also play an important role in determining the ultimate effect of 
therapy with these analogues on tumour growth (Koper et al, 1989). 
SOMATOSTATIN RECEPTORS ON HUMAN TUMOURS 
We have tested a wide variety of human tumours originating from different 
organs for the presence of specific somatostatin receptors. The techniques 
used included somatostatin receptor autoradiography and biochemical 
characterization f receptor-positive tumours with an in vitro binding assay 
showing saturable and high affinity receptors with pharmacological specificity 
for somatostatin (Reubi and Maurer, 1985; Reubi et al, 1986a). 
As mentioned above, somatostatin receptors were observed on most 
GH-producing pituitary adenomas (Reubi and Landolt, 1984) and most 
endocrine pancreatic turnouts and carcinoids (Reubi et al, 1987a,d). An 
example of somatostatin receptor autoradiography is shown in Figure 5. 
In addition, all 27 human meningiomas contained considerable numbers 
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Figure 5. Somatostatin receptors in a case of a human vipoma. ( ) Haematoxylin-eosin tained 
section. (b) Autoradiogram showing total bindings of I:51-204-090. (c) Audoradiogram 
showing non-specific binding (in presence of 10-6M 204-090). Bar = 1 mm. 
of somatostatin receptors (Reubi et al, 1986b, 1989). Receptor density 
varied among tumours from low levels to more than 400fmol per mg 
protein. The tumours had saturable and high affinity receptors with 
pharmacological specificity for somatostatin. Interestingly the normal 
human leptomeninx also contains omatostatin binding sites (Reubi et al, 
1986c). Somatostatin receptors were found on all 27 meningiomas studied 
and EGF receptors were found on 23 of them (Reubi et al, 1989). In some 
cases the coincidental presence of both receptors onthe same tumour cells 
could be excluded: the EGF receptors were found especially at the more 
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'active' necrotic part of the tumour, while somatostatin receptors were 
mainly found on the surrounding tumour tissue. No effect of Sandostatin 
was observed on basal or EGF-stimulated growth of meningiomas in 
culture. 
In glia-derived tumours, there was an inverse relationship between the 
incidence of somatostatin receptors and EGF receptors in individual 
tumours (Reubi et al, 1987c, 1989b): in a majority (five of eight) well- 
differentiated astrocytomas (grade I-II), somatostatin receptors were 
present, but in none (zero of eight) were EGF receptors detected. In 
undifferentiated glioblastomas, the reverse situation was observed: no 
somatostatin receptors were found (0 of 14), but EGF receptors were 
present in the majority of tumours (8 of 14). In grade III astrocytomas both 
somatostatin and EGF receptors were seen. These data suggest hat in 
glia-derived tumours, somatostatin receptors are markers for the well- 
differentiated cases as opposed to EGF receptors. High numbers of somato- 
statin receptors were found in two tumours originating from neuroblasts, 
i.e. ganglioneuroblastoma and medulloblastoma (Reubi et al, 1987c,d). 
No somatostatin receptors were found on prostatic, ovarian, endometrial 
and primary liver cell carcinomas (Reubi et al, 1987d). In addition no 
somatostatin receptors could be detected on any of 12 exocrine pancreatic 
carcinomas (Reubi et al, 1988). However, high affinity somatostatin binding 
sites were also found on a human small cell lung cancer cell line (Taylor et al, 
1988b). 
Finally somatostatin receptors were found to be present on human breast 
cancer samples (Reubi et al, 1987d). In this first small series including 
primary and secondary tumours only 8% were positive. In the two subse- 
quent, larger studies, which included only primary tumours, 15% of the 210 
samples were receptor-positive (Foekens et al, 1989; Papotti et al, 1989). 
Papotti et al (1989) compared the expression of neuro-endocrine markers 
with the presence of somatostatin receptors in 100 human breast cancer 
samples. Somatostatin receptors were found in 17 cases, while nine showed 
neuro-endocrine characteristics. A highly significant correlation was estab- 
lished between the expression of neuro-endocrine markers and somatostatin 
receptor density on these tumours. Somatostatin receptors were found on 
15% of 110 human breast cancer samples (Foekens et al, 1989). The relapse- 
free survival for patients with tumours containing somatostatin receptors 
was significantly longer than for patients with somatostatin receptor- 
negative tumours (82% versus 46% disease-free after 6 years). 
SOMATOSTATIN RECEPTOR IMAGING IN VIVO 
High numbers of specific binding sites with a high affinity for somatostatin 
have been found on a variety of human tumours. In autoradiographic studies a
sharp difference was observed between the presence of receptors on the 
tumour tissue, and low numbers of receptors in the surrounding normal 
tissue. In addition amuch longer inhibitory effect of Sandostatin on tumorous 
hormone secretion, e.g. GH-secreting pituitary tumours compared with 
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normal GH release in man, also points to a selective powerful binding and 
effect of the analogue at the site of the tumour which is probably caused by the 
higher number and/or higher affinity of the somatostatin receptors on these 
tumours. These observations led us to explore, whether itmight be possible to 
detect somatostatin receptor-positive tumours in vivo by administration ofan 
analogue labelled with radioactive iodine (Krenning et al, 1989). 204-090 is a 
somatostatin analogue withtyrosine in position 3, rather than phenylalanine 
which is present at that place in Sandostatin. The biological activities of 
Sandostatin and 204-090 are similar. 123I-bound 204-090 (37-555 MBQ) was 
injected intravenously in patients uspected to have somatostatin receptor- 
positive tumours and planar or ECTimages were made with a gamma camera. 
After the bolus injection of radio-iodinated 204-090 rapid accumulation of 
radioactivity was seen in the liver. About 50% of the activity was cleared from 
the blood-pool within 2min of intravenous injection. Localization of the 
primary tumours and their (previously often unknown) metastases with 
radio-iodinated 204-090 was possible in five of six endocrine pancreatic 
tumours (the sixth patient had a 204-090 receptor-negative insulinoma) and in 
all 12 patients with metastatic carcinoid isease. The detection f metastases 
in lymph nodes, bone and liver points towards the powerful discrimination of 
this technique. It also confirms previous in vitro observations which showed 
that metastases of somatostatin receptor-positive tumours remain receptor 
positive (Reubi et al, 1987a,d). The observed accumulation fradionuclide at 
the site of the tumour after intravenous injection appears to be instantaneous 
and prolonged in contrast to the blood-pool activity, which rapidly decreases. 
An example of a patient with a carcinoid tumour which metastasized into the 
liver and to a lymph node in the left side of the neck is shown in Figures 6a 
and b. The in vivo somatostatin receptor-positive imaging technique also 
revealed that 24 and 48 h scans in most patients till showed considerable 
Figure 6. Gamma-camera pictures 30 minutes after the intravenous administration of 
123I-bound 204-090 in a patient with metastatic carcinoid isease. (a) Liver containing several 
hot spots representing somatostatin receptor-positive m tastases. (b) A lymph node in the left 
side of the neck which also contains ametastasis from the carcinoid tumour. 
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accumulation of radioactivity at the tumour site. This suggests that radio- 
therapy for this type of carcinoma with [3-emitting radionuclides labelled to 
somatostatin analogue might be feasible. 
This easy, harmless technique was also used in the investigation of other 
patients with known or unknown somatostatin receptor-positive tumours. 
Positive scans were obtained in patients with pituitary tumours, neuro- 
blastomas, meningiomas, low-grade astrocytomas and neuro-endocrine 
tumours like paragangliomas nd small cell lung cancers. 
SUMMARY AND CONCLUSIONS 
Somatostatin is a regulatory hormone or tissue factor which plays an 
inhibitory role in the normal regulation of several organ systems, including 
the central nervous ystem, hypothalamus and pituitary gland, the gastro- 
intestinal tract and the exocrine and endocrine pancreas. Sandostatin is an 
analogue of somatostatin which has characteristics which makes it a better 
compound for clinical use than native somatostatin: it inhibits GH prefer- 
entially over insulin. It has a long half-life in the circulation, causing a 
prolonged inhibitory effect in somatostatin-responsive target organs. It is 
active after subcutaneous administration and rebound hypersecretion does 
not occur. Sandostatin is very well tolerated by most patients. 
Somatostatin receptors remain present on a variety of tumours which 
arise in tissues that contain these receptors normally. High numbers of 
somatostatin receptors have been found on GH-secreting pituitary tumours 
and on most metastatic endocrine pancreatic tumours and carcinoids. 
Sandostatin treatment ameliorates clinical symptoms in most acromegalic 
patients while GH hypersecretion a d elevated concentrations of circulating 
IGF-I are well controlled. In most patients hormonal hypersecretion from 
endocrine pancreatic tumours and carcinoids is also suppressed uring 
Sandostatin therapy. This results in an instant improvement in the quality of 
life. There is preliminary evidence of control of turnout growth. 
The presence of high numbers of somatostatin receptors on tumours 
enables in vivo receptor-imaging, with 123iodine coupled to a somatostatin 
analogue. This newly developed technique provides for the first time the 
possibility of localization of the primary tumours and their metastases and a 
prediction of which patients may respond to treatment with Sandostatin. 
Theoretically this somatostatin-receptor imaging technique represents a
new approach which may be extended to other receptor-containing 
tumours. Therefore it may provide a new, powerful alternative to tumour 
localization performed with monoclonal antibody technology. Another 
potential development is the use of [3-emitting isotopes coupled to somato- 
statin analogues for therapeutic rradiation. 
Somatostatin analogues exert potent inhibitory effects on the growth of a 
variety of experimental turnout models in animals. Several mechanisms of 
action have been proposed including the direct antiproliferative effects of 
somatostatin and its analogues in a variety of tumour cell cultures. 
Most well-differentiated human brain tumours like meningiomas and 
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low-grade astrocytomas contain somatostatin receptors, while undifferen- 
tiated brain tumours mainly contain EGF receptors. Fifteen percent of 
human breast carcinomas contain somatostatin receptors; those which do 
have a better prognosis. 
It can be concluded that somatostatin is an endogenous, naturally 
occurring inhibitory growth factor. Therapeutic application of its analogue, 
Sandostatin, is easy and harmless and despite no data being available yet on 
its potential use in the treatment of cancer, preliminary laboratory results 
seem promising. 
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